ArticleBMC cancer2025

Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.

Mengwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.